Capricor Securities Class Action Deadline
Analysis based on 6 articles · First reported Sep 21, 2026 · Last updated Sep 23, 2026
The lawsuit introduces legal and regulatory uncertainty for Paragon Therapeutics, potentially pressuring its stock price and increasing volatility as investors assess the risk of adverse outcomes. The broader biotechnology sector may see minor negative sentiment as the case highlights regulatory and disclosure risks in drug development.
Rosen Law Firm has filed a securities class action lawsuit against Paragon Therapeutics, Inc. on behalf of investors who purchased Capricor securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made materially false and misleading statements and failed to disclose that it adopted changes to the pre-specified statistical analysis plan for its cell therapy Deramiocel without prior FDA agreement, creating a significant risk that the FDA would find the clinical results insufficient for effectiveness and jeopardizing regulatory approval for Duchenne muscular dystrophy treatment. The firm has issued reminders to investors about the September 28, 2026 lead plaintiff deadline. Investors may join the class action without out-of-pocket fees through a contingency fee arrangement. The case is pending in court, and no class has been certified yet. The lawsuit claims investors suffered damages when the true details entered the market.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard